Simple and Fast Assay for Apolipoprotein E Phenotyping and Glycotyping: Discovering Isoform-Specific Glycosylation in Plasma and Cerebrospinal Fluid.
Alzheimer’s disease
Apolipoprotein E
glycan
isoform
mass spectrometry
Journal
Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863
Informations de publication
Date de publication:
2020
2020
Historique:
pubmed:
23
6
2020
medline:
4
6
2021
entrez:
23
6
2020
Statut:
ppublish
Résumé
The mechanisms of how APOEɛ4 allele (APOE4) increases the risk of Alzheimer's disease (AD) pathology have not been fully elucidated. In cerebrospinal fluid (CSF), apoE is heavily glycosylated. To determine the impact of APOE genotype on the relative abundance of apoE protein isoforms and their specific glycosylation patterns in CSF and plasma via a newly developed mass spectrometric immunoassay (MSIA) assay. Total glycosylation and isoform-specific glycosylation were analyzed in plasma and CSF from a group of non-demented older individuals (n = 22), consisting of homozygous ɛ3 and ɛ4 or heterozygous ɛ3/ɛ4, ɛ2/ɛ3, or ɛ2/ɛ4 carriers. The glycan structures were further confirmed after treatment with sialidase. In heterozygous individuals, the apoE3/E2, E4/E2, and E4/E3 isoform ratios were all significantly lower in plasma compared to CSF. For all individuals, a single O-linked glycan was observed in plasma, while two glycans (of the same type) per apoE were observed in CSF. The ratio of glycosylated to total apoE was greater in CSF compared to plasma for all apoE isoforms. In plasma and CSF, a trend of decreasing glycosylation was observed from apoE2 > apoE3 > apoE4. The difference in the percentage of secondary glycosylation in CSF was significantly greater in apoE4 compared to the other isoforms. The new MSIA apoE assay robustly distinguishes among apoE isoforms and glycoforms in plasma and CSF. ApoE4 is the predominant isoform and least glycosylated in CSF. Assessing apoE isoform-specific glycosylation by MSIA may help clarify brain apoE metabolism and AD risk.
Sections du résumé
BACKGROUND
The mechanisms of how APOEɛ4 allele (APOE4) increases the risk of Alzheimer's disease (AD) pathology have not been fully elucidated. In cerebrospinal fluid (CSF), apoE is heavily glycosylated.
OBJECTIVE
To determine the impact of APOE genotype on the relative abundance of apoE protein isoforms and their specific glycosylation patterns in CSF and plasma via a newly developed mass spectrometric immunoassay (MSIA) assay.
METHODS
Total glycosylation and isoform-specific glycosylation were analyzed in plasma and CSF from a group of non-demented older individuals (n = 22), consisting of homozygous ɛ3 and ɛ4 or heterozygous ɛ3/ɛ4, ɛ2/ɛ3, or ɛ2/ɛ4 carriers. The glycan structures were further confirmed after treatment with sialidase.
RESULTS
In heterozygous individuals, the apoE3/E2, E4/E2, and E4/E3 isoform ratios were all significantly lower in plasma compared to CSF. For all individuals, a single O-linked glycan was observed in plasma, while two glycans (of the same type) per apoE were observed in CSF. The ratio of glycosylated to total apoE was greater in CSF compared to plasma for all apoE isoforms. In plasma and CSF, a trend of decreasing glycosylation was observed from apoE2 > apoE3 > apoE4. The difference in the percentage of secondary glycosylation in CSF was significantly greater in apoE4 compared to the other isoforms.
CONCLUSION
The new MSIA apoE assay robustly distinguishes among apoE isoforms and glycoforms in plasma and CSF. ApoE4 is the predominant isoform and least glycosylated in CSF. Assessing apoE isoform-specific glycosylation by MSIA may help clarify brain apoE metabolism and AD risk.
Identifiants
pubmed: 32568201
pii: JAD200203
doi: 10.3233/JAD-200203
pmc: PMC7504994
doi:
Substances chimiques
Amyloid beta-Peptides
0
Protein Isoforms
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
883-893Subventions
Organisme : NIA NIH HHS
ID : P50 AG005142
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG054434
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG055770
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG067063
Pays : United States
Références
Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10804-9
pubmed: 15249677
J Neurosci. 2009 May 27;29(21):6771-9
pubmed: 19474305
Biol Psychiatry. 2018 Feb 15;83(4):347-357
pubmed: 28434655
Glycobiology. 2020 Jan 28;30(2):74-85
pubmed: 31616924
Am J Physiol Regul Integr Comp Physiol. 2012 Nov 1;303(9):R903-8
pubmed: 22933021
J Proteome Res. 2019 Nov 1;18(11):3977-3984
pubmed: 31545048
J Lipid Res. 2018 May;59(5):892-900
pubmed: 29540575
Clin Chim Acta. 2009 Apr;402(1-2):61-6
pubmed: 19138682
Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1977-81
pubmed: 8446617
Metabolism. 1999 Sep;48(9):1184-92
pubmed: 10484062
J Biol Chem. 1989 May 25;264(15):9094-101
pubmed: 2498325
Neuron. 2009 Aug 13;63(3):287-303
pubmed: 19679070
J Neurochem. 2010 Mar;112(6):1619-26
pubmed: 20070866
Biochim Biophys Acta. 2012 Oct;1820(10):1475-80
pubmed: 22565051
Clin Chim Acta. 2008 Feb;388(1-2):123-9
pubmed: 18023277
J Biol Chem. 1986 Oct 15;261(29):13415-21
pubmed: 3020031
Exp Neurol. 2003 Sep;183(1):249-53
pubmed: 12957508
JAMA. 1997 Oct 22-29;278(16):1349-56
pubmed: 9343467
Biochim Biophys Acta. 1987 Jan 13;917(1):148-61
pubmed: 3539206
Biochim Biophys Acta. 2006 Dec;1760(12):1802-9
pubmed: 16982154
J Mol Med (Berl). 2018 May;96(5):361-371
pubmed: 29516132
J Biol Chem. 2016 Dec 30;291(53):27204-27218
pubmed: 27793990
J Biochem. 2017 Jan;161(1):99-111
pubmed: 28053144
Glycobiology. 2009 Apr;19(4):375-81
pubmed: 19095697
J Biol Chem. 1994 Sep 23;269(38):23403-6
pubmed: 8089103
Science. 2002 Jul 19;297(5580):353-6
pubmed: 12130773
Proteomes. 2017 Oct 15;5(4):
pubmed: 29036931
Science. 1993 Aug 13;261(5123):921-3
pubmed: 8346443
Biochem J. 2017 Aug 22;474(17):3045-3058
pubmed: 28729427
J Lipid Res. 2009 Apr;50 Suppl:S183-8
pubmed: 19106071
Clin Chem. 1999 Sep;45(9):1431-8
pubmed: 10471645
J Proteome Res. 2013 Feb 1;12(2):573-84
pubmed: 23234360
Biochem Biophys Res Commun. 2017 Aug 19;490(2):486-491
pubmed: 28624365
Bioanalysis. 2016 Aug;8(15):1623-1633
pubmed: 27396364
Lancet Neurol. 2011 Mar;10(3):241-52
pubmed: 21349439
Nat Methods. 2009 Nov;6(11):809-11
pubmed: 19838169
Am J Pathol. 1994 Nov;145(5):1030-5
pubmed: 7977635
FEBS Lett. 2002 Feb 13;512(1-3):101-6
pubmed: 11852060
Mol Cell Proteomics. 2010 Sep;9(9):1968-81
pubmed: 20511397
Lancet. 2006 Jul 29;368(9533):387-403
pubmed: 16876668
J Neurochem. 2010 Nov;115(4):873-84
pubmed: 20412390
Nat Genet. 1994 Jun;7(2):180-4
pubmed: 7920638
Biochem J. 2000 Jun 1;348 Pt 2:359-65
pubmed: 10816430
Sci Transl Med. 2011 Jun 29;3(89):89ra57
pubmed: 21715678
Biomolecules. 2016 Jan 06;6(1):6
pubmed: 26751493